Author: George A. Bray, MD
Editorial changes - 2009-11-06
Author information and module status
Obesity
Select a section to view guidance statement information on Obesity.
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Quality Measures Quality Measures
What's New
ACP Members can access the full PIER website.

Alert2009-08-24
FDA MedWatch Safety Alert for Orlistat (marketed as Alli and Xenical): Early Communication about an Ongoing Safety Review
New Information2009-06-15
Cardiovascular Evaluation and Management of Severely Obese Patients Undergoing Surgery. A Science Advisory From the American Heart Association
ACP Journal Club Link2009-08-01
ACP Journal Club Bariatric surgery was cost-effective at 2 years for management of type 2 diabetes in obese patients
more>>
FAQs
George A. Bray, MD, is a speaker for Eli Lilly, Amylin Corp., and Merck & Co., received grants from Merck & Co., and Takeda Pharmaceuticals; and has consulted for Sanofi-Aventis, Merck, and Amylin.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.